Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Chief Financial Officer | March 06, 2023 | March 08, 2023 |
| Spyre Therapeutics, Inc.SYRE · Entity 2649 | Chief Financial Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date March 06, 2023 · Filed March 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,115 |
Reported balance
After 2023-03-06 transaction · row 1
1 source rowRow 1 · 2023-03-06 · Sale · Disposed 291 · Balance 59,115 F1: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F2: The transaction was executed in multiple trades in prices ranging from $15.120 to $15.440, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
F2: The transaction was executed in multiple trades in prices ranging from $15.120 to $15.440, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Spyre Therapeutics, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 97,262 |
Reported balance
After 2026-09-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-30 · Exercise / conversion · Acquired 17,500 · Balance 97,262 |
| Common StockSEC Table I · non-derivative | Direct | 79,762 |
Reported balance
After 2026-09-30 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-30 · Sale · Disposed 17,500 · Balance 79,762 F1: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.00 to $90.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 87,262 |
Reported balance
After 2026-10-01 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Acquired 7,500 · Balance 87,262 F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 86,662 |
Reported balance
After 2026-10-01 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-10-01 · Sale · Disposed 600 · Balance 86,662 F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 85,162 |
Reported balance
After 2026-10-01 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-10-01 · Sale · Disposed 1,500 · Balance 85,162 F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 83,062 |
Reported balance
After 2026-10-01 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2026-10-01 · Sale · Disposed 2,100 · Balance 83,062 F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.41 to $92.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 79,991 |
Reported balance
After 2026-10-01 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2026-10-01 · Sale · Disposed 3,071 · Balance 79,991 F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F6: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.54 to $93.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 79,762 |
Reported balance
After 2026-10-01 transaction · row 8
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 8 · 2026-10-01 · Sale · Disposed 229 · Balance 79,762 F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F7: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.54 to $93.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F8: Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.50 · Expires 2033-09-01 | Direct | 319,857 |
Reported balance
After 2026-09-30 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-30 · Exercise / conversion · Disposed 17,500 · Balance 319,857 F9: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.50 · Expires 2033-09-01 | Direct | 312,357 |
Reported balance
After 2026-10-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-10-01 · Exercise / conversion · Disposed 7,500 · Balance 312,357 F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F9: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.00 to $90.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.41 to $92.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F6: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.54 to $93.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F7: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.54 to $93.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F8: Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's continued employment with the Issuer.
F9: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2024 Filed Feb 3, 2024 01:27 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $25.86 | $0.00 |
DisclosureSEC source: 0000950170-24-010901 · ownership.xml · derivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-02-01 F1 · derivative.exercise_date: This option a right to purchase 70,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date. Read SEC document |
| December 22, 2023 Filed Dec 22, 2023 23:00 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantCommon Stock | 134,953 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-072763 · ownership.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,953 F1 · shares: Represents 134,953 restricted stock units ("RSUs") granted under the Spyre Therapeutics, Inc. 2016 Equity Incentive Plan, as Amended and Restated. Each RSU represents a contingent right to receive, upon vesting, one share of common stock, par value $0.0001 per share, of the Issuer. The RSUs vest as to one-fourth on each anniversary of September 1, 2023, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 20:10 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 10,121,441 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0000950170-23-046384 · ownership.xml · derivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,121,441 Underlying: Common Stock · 10,121,441 shares Expires 2033-09-01 F1 · derivative.exercise_date: This option represents a right to purchase 10,121,441 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 291 | $15.26 | $4,441.65 |
DisclosureSEC source: 0001567619-23-004671 · doc1.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,115 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The transaction was executed in multiple trades in prices ranging from $15.120 to $15.440, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 00:05 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 18 | $16.52 | $297.36 |
DisclosureSEC source: 0001567619-23-004270 · doc1.xml · nonDerivative · entry 3 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,406 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 00:05 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,416 | $15.82 | $22,398.71 |
DisclosureSEC source: 0001567619-23-004270 · doc1.xml · nonDerivative · entry 2 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,424 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:58 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 55,800 | $0.00 Strike: $15.82 | $0.00 |
DisclosureSEC source: 0001567619-23-004547 · doc1.xml · derivative · entry 2 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,800 Underlying: Common Stock · 55,800 shares Expires 2033-03-02 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:58 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-004547 · doc1.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,406 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 2 of each year, beginning March 2, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:05 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 416 | $16.17 | $6,725.18 |
DisclosureSEC source: 0001567619-23-004270 · doc1.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,840 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The transaction was executed in multiple trades in prices ranging from $15.990 to $16.320, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-22-017633 · doc1.xml · derivative · entry 2 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,277 Underlying: Common Stock · 5,000 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary measured from May 22, 2019 (the "Vesting Commencement Date") and 1/48th of the shares vest on each monthly anniversary thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 5,000 | $1.68 | $8,403.00 |
DisclosureSEC source: 0001567619-22-017633 · doc1.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 17,400 restricted stock units. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 01:49 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10 | $16.44 | $164.45 |
DisclosureSEC source: 0001567619-22-006494 · doc1.xml · nonDerivative · entry 3 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,256 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). F4 · price: The transaction was executed in multiple trades in prices ranging from $16.44 to $16.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F5 · balance_after: Includes 17,400 RSUs. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 01:49 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 293 | $16.86 | $4,939.72 |
DisclosureSEC source: 0001567619-22-006494 · doc1.xml · nonDerivative · entry 2 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,266 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). F3 · price: The transaction was executed in multiple trades in prices ranging from $16.63 to $17.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 01:49 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 35,300 | $0.00 Strike: $17.67 | $0.00 |
DisclosureSEC source: 0001567619-22-006494 · doc1.xml · derivative · entry 4 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,300 Underlying: Common Stock · 35,300 shares Expires 2032-03-03 F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 01:49 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 13,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006494 · doc1.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,559 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2023, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 420 | $17.75 | $7,456.13 |
DisclosureSEC source: 0001567619-22-006228 · doc1.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,259 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). Shares and RSUs remain subject to a lock-up agreement with the underwriters for the Issuer's follow-on offering in February 2021. F2 · price: The transaction was executed in multiple trades in prices ranging from $17.40 to $18.185, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 4,800 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| December 30, 2021 Filed Jan 5, 2022 02:05 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 55,704 | $0.00 Strike: $20.59 | $0.00 |
DisclosureSEC source: 0001567619-22-000388 · doc1.xml · derivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,704 Underlying: Common Stock · 55,704 shares Expires 2031-08-23 F1 · derivative.exercise_date: On August 24, 2021, the Reporting Person was granted the option subject to a milestone condition. The Compensation Committee of the Issuer certified the achievement of the milestone and commencement of vesting on December 30, 2021 (the "Milestone Vesting Commencement Date"). 1/48th of the shares subject to the option shall vest on each monthly anniversary of the Milestone Vesting Commencement Date, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Milestone Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 22:00 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 12,560 | $20.07 | $252,139.49 |
DisclosureSEC source: 0000899243-21-049940 · doc4.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,679 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $19.88 to $20.31, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 5,800 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 22:50 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $29.74 | $0.00 |
DisclosureSEC source: 0001567619-21-007651 · doc1.xml · derivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2031-04-01 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from April 1, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.